As IL-6 is thought to play a causative role in atherosclerosis, IL-6 blockade may decrease the incidence of cardiovascular events, as observed with anti-TNF therapy.20 Further investigation will be required to evaluate whether tocilizumab might increase the risk of developing ischaemic heart disease. This evidence concerns the gene IL6 and atherosclerosis.